|
Dan Shochat, Ph.D. led the development of Bexxar�, a radioiodinated antibody for the treatment of Non-Hodgkin's Lymphoma, which was approved by the FDA in June 2003. At American Cyanamide Co., Dr. Shochat led the development, in collaboration with Celltech, of the first approved antibody-drug conjugate, Mylotarg�; Invented the technology and single-vial formulation, and then developed the FDA-approved in vivo tumor-imaging reagent CEA-Scan�. Dr. Shochat is currently Executive Vice President of Development of KaloBios, Inc. Formerly, Dr. Shochat was Director, Product R&D, Immunomedics; Director of Biotechnology Development at American Cyanamid Co.; Senior Vice President and Chief Scientific Officer Coulter Pharmaceutical, Inc.; Ph.D. in Biochemistry from L.S.U. Medical School in New Orleans, LA. | 